Researchers at TSRI describe an unusual antibody configuration that effectively neutralizes HIV by binding to sugars on its surface. This breakthrough could lead to designing an effective AIDS vaccine by stimulating the human immune system to produce similar broadly neutralizing antibodies.
Researchers have identified small chemical molecules that can direct embryonic stem cells to become neurons, paving the way for potential treatments of neurodegenerative diseases like Parkinson's and Type 1 diabetes. The study provides important insights into the molecular mechanism controlling stem cell fate and may lead to new therap...
Researchers solved the atomic structure of pilin proteins in Pseudomonas aeruginosa and Vibrio cholerae, essential for bacterial movement and infection. This knowledge provides crucial insights for developing novel antibiotics and vaccines against these deadly diseases.
Researchers have created a new vaccine that stimulates the immune system to clear nicotine from the body, potentially aiding in smoking cessation. The vaccine induces antibodies that can neutralize nicotine before it reaches the brain.
TSRI scientists have identified rare genetic mutations in the TLR4 gene that increase susceptibility to meningococcal sepsis, a devastating disease with a 12% case fatality rate. The study suggests that individuals with these mutations may be protected from severe sepsis through prophylactic treatment.
Researchers create a hybrid compound combining an antibody with a traditional anticancer drug, effectively steering the hybrid towards cancer cells. The approach shows promise in preclinical studies and could be used to design hybrids against multiple cancers.
Researchers at Scripps Research Institute discovered the first noxious cold receptor, ANKTM1, which detects 'noxious' cold temperatures and allows an influx of positively charged ions into axons. This finding may lead to pain-modulating drugs.
Researchers at Scripps Research Institute have found that the human body produces ozone as part of a mechanism to protect itself from bacteria and fungi. The discovery suggests a new role for neutrophils and antibodies in the immune system, potentially leading to new treatments for inflammatory diseases.
Researchers develop method to prevent amyloid formation by stabilizing the native state of proteins, preventing disease-associated subunits from contributing to fibril formation. This approach has potential therapeutic applications for various amyloid diseases, including familial amyloid polyneuropathy and cardiac disorders.
Researchers create a new, cost-effective way to produce human therapeutic proteins using algae. They can now make large quantities of antibodies and other proteins much cheaper than traditional methods.
Scientists have created a completely autonomous organism that uses 21 amino acids, enabling site-specific incorporation of novel amino acids into proteins. This breakthrough expands the genetic code's capabilities and paves the way for innovative medical research and protein modification technologies.
The research aims to identify key players in the innate immune system and study gene expression patterns triggered by microbial invasion. The grant will support a systems biology approach to understand how the system behaves as a whole, ultimately informing novel hypotheses.
Researchers create first binary enzyme using only two nucleotides, A and U, to demonstrate Darwinian evolution in a genetic system. This breakthrough supports the theory that early life on earth may have been restricted to two bases.
Scientists have developed a way to measure protein flexibility using lasers, revealing a dynamic process in antibody-antigen recognition. The technique allows for the detection of rapid molecular motions, suggesting that antigen recognition may not be a simple lock-and-key mechanism.
Researchers at TSRI describe experiments showing Opn4 gene is crucial for maintaining circadian rhythms, enabling organisms to adapt to daily changes. The discovery may lead to strategies for correcting sleep disorders and jet lag.
Researchers have solved the structure of fatty acid amide hydrolase (FAAH), an enzyme that metabolizes endocannabinoids like anandamide, which provide natural pain relief. By inhibiting FAAH, scientists aim to increase the longevity of these molecules, potentially leading to effective and long-lasting pain relief without side effects.
Scientists at The Scripps Research Institute report that antibodies can kill bacteria through the production of hydrogen peroxide, which also leads to the formation of ozone. This discovery opens up possibilities for new antibody-mediated therapies for conditions ranging from bacterial and viral infections to cancer.
Researchers have developed a sepsis vaccine that provides outstanding protection by reducing inflammatory chemicals by nearly 95%. The vaccine targets endotoxins, which trigger the immune system's response to infection.
Researchers designed a DNA vaccine that stimulates the immune system to recognize and attack proliferating blood vessels in tumors, depriving them of oxygen and nutrients. The vaccine has shown promise in preventing effective angiogenesis and inhibiting tumor growth, offering potential for novel cancer therapies.
Researchers at Scripps Research Institute have developed a new treatment for Gaucher disease by using small molecules to partially correct the genetic defect that underlies most cases of the disease. The therapy targets the most common mutation and could be more convenient and less costly than current enzyme replacement therapy.
Researchers found that nornicotine permanently modifies proteins, affecting their function, and reacting with steroids to form advanced glycation endproducts, linked to diseases like diabetes and Alzheimer's. The study highlights the need for more research into nicotine metabolites' consequences.
Researchers at TSRI identified over 2,400 proteins in Plasmodium falciparum, the most deadly malaria parasite, which may lead to new vaccine targets. The study sheds light on how the pathogen causes malaria and could help scientists understand its lifecycle.
Researchers at Scripps Research have created a novel technology to detect single nucleotide polymorphisms (SNPs) in malaria parasites, enabling the identification of drug-resistant strains and mapping their spread. The new approach uses gene chips to analyze thousands of SNPs simultaneously.
Researchers at TSRI have uncovered a mechanism by which plants adjust their flowering cycles to optimize productivity. By manipulating the timing of plant development, crops may be able to produce faster and more nutritious yields.
Researchers seek compounds to inhibit angiogenesis, a common cause of vision loss. A new class of anti-angiogenic molecules has shown promise in pre-clinical studies, with 70% inhibition in 100% of cases.
Researchers at TSRI have developed a technique to selectively deliver adult stem cells into the eye, which can stimulate vessel growth and address inherited retinal degenerations. The cells can incorporate into the vasculature and make it normal, or be loaded with antiangiogenics to selectively wipe out the formation of new blood vessels.
Researchers at Scripps Research Institute suggest administering an injection of fresh T cells after chemotherapy or irradiation to increase anti-tumor effect. This approach could potentially reduce collateral damage and improve treatment outcomes for various cancers.
Researchers combine a gene that shuts off angiogenesis with a nanoparticle that selectively targets cancer tumor cells, effectively cutting off their blood supply and killing the tumor. This approach shows strong regression of large tumors in every system tested.
Researchers at Scripps Research Institute have identified the first temperature-sensing molecule found in keratinocytes, the major type of cell in the skin, which can detect warm and hot temperatures above 33°C. This discovery opens up new possibilities for pain therapeutics.
Researchers have identified gamma-delta T cells as a crucial component of the immune system in wound repair. These cells recognize an antigen released by keratinocytes during injury and produce growth factors that help proliferate epithelial cells, leading to wound closure.
Scientists at Scripps Research Institute have identified human antibodies that can recognize spore surfaces, enabling the detection of anthrax and other bacterial spores. These antibodies could be used to passively immunize individuals exposed to anthrax, providing a simple and inexpensive treatment option.
Researchers at The Scripps Research Institute develop a new drug-discovery strategy using click chemistry to create a potent inhibitor against the enzyme acetylcholinesterase. This breakthrough allows the target enzyme to select and catalyze its own synthesis, resulting in a highly effective treatment for Alzheimer's disease.
Researchers at TSRI report a novel synergistic folding mechanism in two transcriptional proteins, CBP and p160, which become active when brought together. This discovery sheds light on the biological functions of intrinsically unstructured proteins and their role in cancer and other diseases.
Researchers have successfully attached molecules to the surface of a virus, creating a novel method for immobilizing large molecules on viral surfaces. This technique has potential applications in nanotechnology, materials science, and medicine.
Researchers at TSRI develop a method for controlling chemical reactions by encapsulating molecules in nanocapsules, enabling self-regulatory amplification and exponential growth. This discovery offers a new approach to controlling reactivity without the need for autocatalysts.
A large DNA-based study revealed that only a small percentage of people with the genetic mutation for hereditary hemochromatosis develop symptoms. Most individuals with the mutation remain asymptomatic and do not experience the disease's life-shortening effects.
Scientists at Scripps Research Institute have discovered a fragment of the human protein TrpRS that inhibits angiogenesis, offering new hope for treatments of age-related macular degeneration and diabetic retinopathy. The truncated form of TrpRS appears to be more potent than existing antiangiogenic compounds.
Researchers identify Mus81, a resolvase enzyme in fission yeast, as a crucial component of genetic recombination. The discovery has potential implications for cancer therapy, as the enzyme plays a role in cell replication and DNA repair.
Researchers at Scripps Research Institute develop a therapy to prevent misfolding diseases by incorporating a protein suppressor into the diseased protein, stabilizing it and preventing fibril formation. This approach may also work for other diseases with similar protein-protein interactions.
Researchers at Scripps Research Institute have solved the first high-resolution structure of a membrane transporter, which can help design new drugs against antibiotic-resistant bacteria and certain cancer cells. The breakthrough could lead to increased efficacy of chemotherapy agents.
Researchers found that antibodies can convert oxygen into hydrogen peroxide, a previously unknown mechanism that could enhance their killing power and contribute to autoimmune diseases like lupus. This discovery opens up exciting possibilities for new antibody-mediated therapies for bacterial, viral, and cancer treatments.
Researchers create antibody Fab D18, which blocks prion propagation and clears infectious prions from cell cultures. This breakthrough provides a potential therapeutic target for a human drug to cure established infection.
Researchers at The Scripps Research Institute have solved the structure of a neutralizing antibody against HIV, marking an important milestone in the development of an effective vaccine. This breakthrough demonstrates that the human immune system can produce antibodies effective against HIV and provides a template for vaccine design.
Researchers at Scripps Research Institute develop cyclic peptide nanotubes that disrupt bacterial cell walls, killing deadly pathogens. These 'nanotube' stacks have strong bactericidal activity and may minimize resistance development.
Researchers at The Scripps Research Institute propose a new therapeutic target to prevent tissue damage caused by stroke, complementing current clot-dissolving treatments. Administering a Src kinase inhibitor within hours of stroke may reduce brain injury and potentially prevent long-term neurological damage.
Researchers at TSRI have cloned the TOC1 gene, which regulates circadian rhythms in plants, providing insight into how plants adapt to daily environmental changes. The study's findings suggest that understanding plant internal clocks may also elucidate clock mechanisms in other species, including humans.
A new study suggests that human aging and its associated diseases can be traced to gradual increases in cell division errors in tissues throughout the body. Altered gene expression results in cells with diminished function, leading to aging.
Researchers at TSRI demonstrate that the immune system can cure viral infections without destroying infected cells. Nondestructive antiviral mechanisms triggered by inflammatory cytokines contribute to viral clearance, preserving organ function.
Researchers found that angiogenesis, the formation of new blood vessels, contributes to arthritic disease progression. Treatment with an integrin antagonist reduced joint swelling, pannus formation, and cartilage erosion in animal models.
Researchers at Scripps Research Institute and R.W. Johnson Pharmaceuticals have developed a new class of antibacterial agents that inhibit two-component signal transduction systems, a key regulatory mechanism in bacterial virulence. These inhibitors show promise as a potential tool against antimicrobial-resistant pathogens.